Skip to Content

Bluebird Bio, Inc.

Company NameBluebird Bio, Inc.
Stock SymbolBLUE

On December 1, 2018, Bluebird issued a press release informing investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” Then on December 3, 2018, Seeking Alpha published an article asserting that “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” On this news, shares of Bluebird stock price fell $6.39 per share, or 5.2%, to close at $116.50 on December 3, 2018, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Bluebird Bio, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd